Idana | Updates

By Lucas Spohn

Idana on Site – What the Patients say!


Dear Companists,


There are pioneers who look for new paths in every field. William Osler was one of them. In the 19th century, the physician revolutionized the training of prospective doctors and advocated involving the patient in the search for the correct diagnosis: “Listen to your patient, he might be telling you the diagnosis!”

Idana’s team has also adopted Osler’s mission statement. For this reason, we filmed interviews with patients, in which we introduced them to Idana and asked them about their impressions, concerns, and hopes. We will be able to share the final video with you in late March. However, we can already tell you the results of our conversations with Idana testers in this update.


“Listen to your users, they might tell you what they need”

Every person is different, and that is particularly true for patients. Therefore, we asked the participants what they expect of a good doctor before we presented Idana to our test patients for the first time. We discovered different emphases depending on age, lifestyle, and previous experiences with doctors: While the employed young man expects a well-organized office with short waiting periods, the elderly lady values the doctor’s professional and social competence above all else: If the doctor takes the time to answer questions and explain medical treatments, she is willing to wait longer – what may be a no-go for one patient may still be acceptable to another.

We receive mixed responses when we tell our testers about a software that collects all relevant information in advance via tablet or smartphone, and which transmits these to the doctor before the appointment. All of our test patients have had to complete standardized anamnesis questionnaires in the past. Not only the elderly lady, but also our third Idana tester, a member of the 50+ generation, expresses doubts about completing the survey on the tablet successfully. The fact that the Idana questionnaires can be used illness-specifically and not only to obtain basic data makes them curious nevertheless.


Idana interviews test patients


Great potential, versatile usage

Contrary to all concerns, none of our test patients have problems using the tablet. And user experience? “This is awesome,” says our tech-savvy tester. Opting out of free response fields turns out to be the right choice: The pre-figured answers facilitate usability not only our older patients, they also provide support answering important questions precisely.

Usability is one thing, added value is another. We encourage our test patients to express concerns and ask questions. We repeatedly have to explain how we protect confidential patient data from unauthorized access via end-to-end encryption. One concern expressed is hat doctors may not reinvest the time gained into a more thorough conversation, but instead use Idana to process more patients – concerns that are based on bad experiences, and are justified to some extent. Our test patients, however, are hopeful: hopeful, that Idana will improve communication with the doctor, will open up new communication channels, and make doctor’s visits more convenient.


Greetings from Freiburg,
Lucas Spohn


Only registered Companists can comment. Please log in to leave a comment.


Investments in startups and growth companies offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, investments in startups or growth companies are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by diversifying the amount they invest in startups and growth companies and not investing the entire amount in one startup or growth company. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the investors on Companisto are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the investors (Companists) – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, investments in startups and growth companies are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 500,000




22.58 %

Share Offered

Please note
The acquisition of this asset involves considerable risks and can lead to the complete loss of the assets used. The expected yield is not guaranteed and may turn out to be lower.
Contact Us
If you have any questions about investing on Companisto, please contact our service team:

Toll-free phone number for investors

0800 - 100 267 0 (DE)
0800 - 100 267(AT / CH)

We are available Monday through Friday between 9 a.m. – 7 p.m.

For companies
Apply for financing Investment Model FAQ for Companies
Investor Support
Please register in order to see the complete profile of Idana.
Already registered?    Log in